tailieunhanh - Expression of biomarkers in canine mammary tumours

Biomarkers identifiable in tumours have potential use in early diagnosis, staging, prognosis and assessment of response to therapy. This paper describes the immunohistochemical expression of a few reliable biomarkers in post surgical canine mammary gland tumour (CMGT). Immunohistochemical expression of biomarkers in canine mammary tumours was carried out in forty three mammectomised tissue samples. The intensity and distribution of immunostaining of the biomarkers in histological types of CMGT was studied. PCNA showed weak nuclear staining in benign tumour and strong nuclear staining in malignant tumours. Bcl 2 showed weak cytoplasmic staining in benign tumours and moderate cytoplasmic staining in 10-20% of epithelial cells in malignant tumours. Cytokeratin 8/18 expression was strong in >50% of epithelial cells in benign and malignant tumours. Vimentin expression was specific with strong cytoplasmic staining in the stromal fibrous tissue, stromal fusiform cells, myoepithelial cells in tubules, spindle cells, chondroid tissue and lipocytes. CEA expression was negative in benign tumours. Malignant tumours expressed moderate membranous to cytoplasmic staining in 10-20% of luminal epithelial cells. MUC 1 expression was weak membranous staining in | EXCELLENT PUBLISHERS International Journal of Current Microbiology andAppliedSciences ISSN 2319-7706 Volume 8 Number 05 2019 Journal homepage http Original Research Article https Expression of Biomarkers in Canine Mammary Tumours N. Muniappan S. Ramesh S. Hemalatha Mohamed Shafiuzama and . Preetha Department of Veterinary Pharmacology and Toxicology Madras Veterinary College Chennai-7 Tamil Nadu Veterinary and Animal Sciences University India Corresponding author ABSTRACT Keywords Canine mammary tumours Biomarkers immnuno histochemistry Article Info Accepted 12 April 2019 Available Online 10 May 2019 Biomarkers identifiable in tumours have potential use in early diagnosis staging prognosis and assessment of response to therapy. This paper describes the immunohistochemical expression of a few reliable biomarkers in post surgical canine mammary gland tumour CMGT . Immunohistochemical expression of biomarkers in canine mammary tumours was carried out in forty three mammectomised tissue samples. The intensity and distribution of immunostaining of the biomarkers in histological types of CMGT was studied. PCNA showed weak nuclear staining in benign tumour and strong nuclear staining in malignant tumours. Bcl 2 showed weak cytoplasmic staining in benign tumours and moderate cytoplasmic staining in 10-20 of epithelial cells in malignant tumours. Cytokeratin 8 18 expression was strong in 50 of epithelial cells in benign and malignant tumours. Vimentin expression was specific with strong cytoplasmic staining in the stromal fibrous tissue stromal fusiform cells myoepithelial cells in tubules spindle cells chondroid tissue and lipocytes. CEA expression was negative in benign tumours. Malignant tumours expressed moderate membranous to cytoplasmic staining in 10-20 of luminal epithelial cells. MUC 1 expression was weak membranous staining in 10 of apical portion of luminal epithelial cells in benign tumours. Overexpression .

• Y khoa - Dược
• Expression of biomarkers
• Canine mammary tumours
• Biomarkers immnuno histochemistry
• Assessment of response
• Immunohistochemical expression
• BMC Cancer
• Advanced gastric cancer
• Predictive biomarkers
• Tumor PD L1 expression
• Progression free survival
• BMC Bioinformatics
• Mining ABs
• Associated biomarkers
• Meta analysis
• Combination effects
• Gene expression
• Prostatic neoplasms
• Tumor markers
• Quantitative PCR
• Diagnostic biomarkers
• Cancer biomarkers
• Differential expression
• Expression complexity
• Regulation probability
• Transcriptomics data
• Bioinformatics analysis
• Clear cell renal cell carcinoma
• Molecular prognostic biomarkers
• Gene expression omnibus
• Gastric cancers
• Cancer stem cells
• Expression signature
• Biomarkers underlying CD133
• CpG methylation
• Breast cancer
• Sporadic breast tumors
• BRCA 1 expression
• HER 2 positive breast tumors
• Latent infection
• Mycobacterium tuberculosis
• Molecular diagnostic
• BMC Pulmonary Medicine
• Acute respiratory distress syndrome
• Mechanical ventilation
• Staphylococcus aureus
• Idiopathic pulmonary fibrosis
• Gene expression analysis
• Gene signature
• IPF subtyping
• BMC Veterinary Research
• Japanese quails
• Zinc oxide nanoparticles
• Antioxidant enzymes
• Gastric cancer
• Trastuzumab therapy
• HER2 positive gastric cancer
• báo cáo hóa học
• công trình nghiên cứu về hóa học
• tài liệu về hóa học
• cách trình bày báo cáo
• Hepatitis C virus
• miR 122
• miR 134
• miR 424
• miR 629
• Receiver operating characteristic
• Non small cell lung cancer
• Differentially expressed genes
• Regulatory network
• Microarray data analysis
• Circular RNA
• Expression profiles
• Bioinformatic analysis
• Multiple myeloma
• Diagnostic and prognostic value
• Familial breast cancer
• Tissue microarray
• Identify biomarkers
• Mutation carriers
• RNA sequencing
• Thyroid carcinomas
• Thyroid tumours
• Circulating miRNAs
• Triple negative breast cancer
• Circulating biomarkers
• Plasma versus tissue
• ROC curves
• Cancer therapy
• Alternative splicing
• Prognostic biomarkers
• Helicase like Transcription Factor
• Gene hypermethylation
• Potential prognostic biomarkers
• Carbonic anhydrase IX
• Intrahepatic cholangiocarcinoma
• Beclin 1
• Tumor biomarkers
• Human epidermal growth factor receptor 2
• Transmembrane tyrosine kinase receptor
• Lipid rafts
• Early detection
• Human papilloma virus 16
• Major risk factor
• Head and neck squamous cell carcinoma
• Tumor tissues
• Colorectal cancer
• Broadened therapeutic
• Reduce angiogenesis
• Vascular endothelial growth factor